



# UNITED STATES PATENT AND TRADEMARK OFFICE

14

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/007,869

11/08/2001

Stewart Paton Granger

J6666(C)

6511

201 7590 03/21/2007  
UNILEVER INTELLECTUAL PROPERTY GROUP  
700 SYLVAN AVENUE,  
BLDG C2 SOUTH  
ENGLEWOOD CLIFFS, NJ 07632-3100

EXAMINER

COTTON, ABIGAIL MANDA

ART UNIT

PAPER NUMBER

1617

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

3 MONTHS

03/21/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

<b>Office Action Summary</b>	Application No. 10/007,869	Applicant(s) GRANGER ET AL.	
	Examiner Abigail M. Cotton	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 12 January 2007.
- 2a) ☒ This action is **FINAL**.      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1,2,4-7,9-12 and 14-18 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-2, 4-7, 9-12 and 14-18 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

This office action is in response to the amendments and remarks submitted on January 12, 2007. Claims 1-2, 4-7, 9-12 and 14-18 are pending in the application and are being examined on the merits herein.

Applicants' arguments regarding the rejections of the claims over the prior art have been fully considered but they are not persuasive. The following rejections have been necessitated by Applicants' amendments to the claims.

#### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-2, 4-7, 9-12 and 14-18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contain subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. In particular, the recitation that the first composition does not come "into contact with the second composition when being stored," as recited in claims 1, 6 and 11, does not find support

Art Unit: 1617

in the specification as originally filed. The specification discloses, for example, that the compositions can be provided in a dual compartment package, such as a single bottle/jar with a division separating an interior into first and second compartments, so the compositions are retained separately (see page 30, lines 15-23, in particular), but is silent as to whether the first and second compositions come into contact in the package, or whether such contact does or does not occur during storage. Accordingly, as the specification as originally filed does not provide support for claims 1, 6 and 11 as amended, the claims are deemed to add impermissible new matter. Appropriate correction is required. Claims 2, 4-5, 7, 9, 12 and 14-18 are rejected as being dependent upon indefinite claims.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-2, 4-7, 9-12, 14-5 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,914,116 to Soares et al, issued June 22, 1999, in view of U.S Patent No. 5,965,518 to Nakatsu et al, published October 12, 1999, and further in view of U.S. Patent No. 5,976,555 to Liu et al, issued November 2, 1999.

Suares et al. teaches a method for a skin treatment regime and product that includes a first composition containing at least one active and functioning to impart a first benefit to skin, and a second composition that includes a second different active and imparts a second benefit to skin (see abstract, in particular.) Suares et al. teaches that the first and second compositions are stored in respective separate containers, which are joined together (see abstract and column 2, lines 1-14, in particular.) Suares et al. teaches that the two compositions are kept separate because single formulations often compromise the performance of the severally combined actives (see column 1, lines 15-25, in particular.) Thus, Suares et al. teaches providing a first composition in a first compartment, and a second composition in a second compartment, where the compositions in each respective containers are isolated from one another, and where the first and second compartments are joined together, as recited in claim 1.

With regards to the types of compositions provided, Suares et al. provides examples of first compositions and second compositions where the first composition is a cleanser and the second composition is an anti-acne preparation (see Table I, second entry, in particular), and also where the first composition is a sunscreen and the second composition is an anti-wrinkle cream (see Table I, tenth entry, in particular.) Suares et al. teaches that anti-wrinkle compositions and anti-acne preparations can contain actives such as retinoids, where suitable retinoids include retinol, retinoic acid or C<sub>1</sub>-C<sub>20</sub> esters of retinol and retinoic acid (see column 4, lines 20-25 and 59-65 and column 5,

lines 12-16, in particular.) Suares et al. teaches levels of retinoids in the compositions may be from 0.00001 to 2% (see column 4, lines 60-65, in particular), which is an amount that overlaps with that recited in claim 1. Furthermore, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the amount of the retinoid provided in the anti-acne or anti-wrinkle composition, according to the guidance provided by Suares et al, to provide a composition having desired properties. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.) Suares et al. also exemplifies a sunscreen composition suitable for the two-composition product having a fragrance (see column 8, Table II, in particular.)

Accordingly, Suares et al. teaches providing an anti-wrinkle or anti-acne composition corresponding to the first composition as recited in claim 1, and teaches providing the first composition and a second composition (such as a sunscreen or cleanser composition) in first and second compartments isolate the compositions and that are also joined, as recited in claim 1.

Suares et al. does not specifically teach a second composition comprising the specific retinoid booster, such as citral, citronella, etc, as recited in claim 1. Suares et

Art Unit: 1617

al. also does not specifically teach that the compartment having the retinoid keeps the retinoid composition out of contact with oxygen, as recited in claim 1.

Nakatsu et al. teaches a fragrance composition that can include non-aromatic terpenoid compounds such as citral, citronellol, geraniol and linalool, and that is suitable for various products (see abstract, and column 3, lines 25-45, in particular), and thus teaches the retinoid boosters as recited in claim 1. Nakatsu et al. teaches that the fragrance composition can be included in a skin cream, hand and body lotion, sunscreen, and other compositions (see claim 9, in particular.) Thus, Nakatsu et al. teaches fragrances and fragrance compositions that are suitable for topical application to skin and can be used in topical formulations such as sunscreens.

Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the fragrances and fragrance compositions of Nakatsu et al. in the compositions of Soares et al, and in particular in the sunscreen composition of Soares et al., because Soares et al. exemplifies such sunscreens have fragrances, and Nakatsu et al. teaches fragrances that are suitable for topical compositions such as sunscreens. Thus, one of ordinary skill in the art would have been motivated to provide the fragrances in the composition of Soares et al. with the expectation of providing a fragrance that is suitable for topical use and that is known to be suitable for combination with sunscreen compositions:

Regarding the amount of the fragrances provided, as recited in claim 1, it is noted that Nakatsu et al. teaches that the fragrance composition itself can comprise between 20 and 80% non-aromatic terpenoids, such as those claimed (see abstract, in particular), and Soares et al. exemplifies a composition having 0.30% of a fragrance (see Table II, in particular), which is an amount that meets the limitation of the claim. Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the amount of the fragrance provided in the composition, according to the guidance provided by Nakatsu et al, to provide a composition having desired properties. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

Accordingly, the teachings of Soares et al. and Nakatsu et al. render obvious a skin care product comprising first and second compartments for storing compositions, the compartments being joined, where the product comprises an anti-wrinkle cream having the retinoid first composition as claimed, and a sunscreen having the retinoid booster second composition (i.e. comprising fragrances), as recited in claim 1.

The combination of Soares et al. and Nakatsu et al. does not render obvious providing a compartment that keeps the retinoid composition out of contact with oxygen as recited in claim 1, such as a compartment made out of aluminum.



Liu et al. teaches that it is known that retinoids such as retinol, retinal and retinyl esters quickly lose their activity and oxidize in conventional skin care products (see column 2, lines 35-55, in particular). Liu et al. teaches that the oxidation of skin care compositions can be reduced by excluding oxygen permeation, particularly by fabricating the container walls from aluminum (see column 12, lines 40-68, in particular), and thus teaches providing an aluminum container that keeps the retinoid composition out of contact with oxygen, as recited in claim 1, and thus also provides a "stable" skin care product.

Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to modify the two compartment product teachings of Soares et al. to provide a compartment made of aluminum for the retinoid composition that keeps the retinoid out of contact with oxygen, because Soares et al. teaches the desirability of providing the two-compartment product to maximize the effectiveness of the separate compositions, and teaches providing retinoids in one of the compositions, while Liu et al. teaches that it is known that retinoids such as those taught by Suarez et al. can easily oxidize and lose their effectiveness, and that such oxidation can be reduced by providing aluminum containers. Thus, it is considered that one of ordinary skill in the art would have been motivated to provide the aluminum compartment to store the retinoid composition in the product of Soares et al, with the expectation of improving the effectiveness of the retinoid composition. Accordingly,

Art Unit: 1617

claim 1 is obvious over the teachings of Soares et al. in view of Nakatsu et al. and further in view of Liu et al.

Regarding the recitation in claim 1 of "the first composition not being chemically degraded by the second composition and not coming into contact with the second compositions when being stored in the first compartment," it is noted, as discussed above, that Soares et al. teaches the two compositions in the different compartments are kept separate because single formulations often compromise the performance of the severally combined actives (see column 1, lines 15-25, in particular.) Thus, it is considered that Soares et al. teaches that the compositions are isolated in each compartment so that the actives in each composition will not compromise the performance of one another, and thus teaches compartments in which the compositions are not degraded by each other and do not come in contact when being stored, as recited in claim 1.

Furthermore, regarding the recitations that "the first composition not being chemically degraded by the second composition and not coming into contact with the second compositions when being stored in the first compartment," and "the second composition potentiates the action of the retinoid upon contact," it is noted that as combined teachings of Soares et al, Nakatsu et al. and Liu et al. renders the claimed product and compositions obvious, the property of such a claimed product/compositions will also be rendered obvious by the prior art teachings, since the properties, namely the

Art Unit: 1617

avoidance of degradation, lack of contact, and potentiation of action on contact, are inseparable from its composition. Therefore, if the prior art teaches the composition or renders the composition obvious, then the properties are also taught or rendered obvious by the prior art. *In re Spada*, 911 F.2d 705, 709, 15 USPQ 1655, 1658 (Fed. Cir. 1990.) See MPEP 2112.01. The burden is shifted to Applicant to show that the prior art product does not possess or render obvious the same properties as the instantly claimed product.

Regarding the recitation that the components of the second composition act are “retinoid boosters”, as recited in the claims, it is noted that the retinoid boosting activity of a compound is a property thereof, and a product and its properties are inseparable. *In re Papesch*, 315 F.2d 381, 137 USPQ 43 (CCPA 1963). Accordingly, the composition rendered obvious by the combined references would, absent evidence to the contrary, meet the limitations pertaining to the retinoid boosting activity of the compound used therein.

Regarding claims 6 and 11, *Suares et al*, *Nakatsu et al*. and *Liu et al*. render obvious a product having first and second compartment that are joined together, and that isolate the compositions therein, the first composition keeping out oxygen and being made of aluminum, with a first composition having a retinoid as recited in the claims, and a second composition having a fragrance corresponding to the retinoid boosters as recited in the claims, as has been discussed above. While the references

Art Unit: 1617

do not specifically teach providing the amount ranges of retinoid and retinoid booster as recited in the claims, the references do teach providing amounts that are close to and/or overlap with the amounts as recited. Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the amount of retinoids and/or fragrances provided in the composition, according to the guidance provided by Soares et al., Nakatsu et al and Liu et al, to provide a composition having desired properties. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

Regarding claims 2, 7 and 12, it is noted that Nakatsu et al. teaches the fragrances citral, citronellol and linalool, among others, may be provided in the composition, while the teachings of Soares et al. and Nakatsu et al. render obvious providing a fragrance composition in the amount as claimed, and thus the references teach that at least two fragrances (retinoid boosters) may be provided, as recited in the claims.

Regarding the methods of claims 4-5, 9-10 and 14-15, Soares et al. teaches that the retinoid may be a part of an anti-acne composition, and also acts as an anti-wrinkle agent (see column 4-5, in particular), and thus teaches providing the composition on skin for the treatment of acne and wrinkles. Soares et al. also teaches that the

Art Unit: 1617

compositions can comprise emollients and humectants (see column 5, lines 35-40, in particular), which moisturize and condition the skin. Furthermore, as the combined teachings of Soares et al, Nakatsu et al. and Liu et al. renders the claimed composition obvious, the property of such a claimed composition will also be rendered obvious by the prior art teachings, since the properties, namely the conditioning of skin upon application, or the mimicking of the effect of retinoic acid such as the treatment of acne or wrinkles, upon application to skin, are inseparable from its composition. Therefore, if the prior art teaches the composition or renders the composition obvious, then the properties are also taught or rendered obvious by the prior art. In re Spada, 911 F.2d 705, 709, 15 USPQ 1655, 1658 (Fed. Cir. 1990.) See MPEP 2112.01. The burden is shifted to Applicant to show that the prior art product does not possess or render obvious the same properties as the instantly claimed product. Thus, the methods as taught by Soares et al, Nakatsu et al. and Liu et al. necessarily result in skin conditioning, treatment of acne, wrinkles, etc, as recited in the claims.

Regarding claim 17, Soares et al. teaches that the composition can comprise an emollient such as esters of fatty acids and fatty acids (see column 5 line 35 through column 6, line 60, in particular), and thus teaches the emollients as claimed. Regarding the amounts of the emollients, Soares et al. teaches that the emollients can be provided as a part of the carrier, which can be in an amount of from 30 to 99.9% (see column 5, lines 35-42, in particular.) Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or

Art Unit: 1617

optimize the amount of emollient provided in the composition, according to the guidance provided by Soares et al, to provide a composition having desired properties. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,914,116 to Soares et al, issued June 22, 1999, in view of U.S Patent No. 5,965,518 to Nakatsu et al, published October 12, 1999, and further in view of U.S. Patent No. 5,976,555 to Liu et al, issued November 2, 1999, as applied to claims 1-2, 4-7, 9-12, 14-5 and 17 above, and further in view of JP 04183797 to Kobayashi et al, published June 30, 1992.

Soares et al, Nakatsu et al. and Liu et al, are applied as discussed for claims 1-2, 4-7, 9-12, 14-5 and 17 above, and render obvious the product having first and second compartment that are joined together and that isolate the compositions therein, the first composition keeping out oxygen, with a first composition having a retinoid as recited in the claims, and a second composition having a fragrance corresponding to the retinoid boosters as recited in the claims. Specifically, Soares et al, Nakatsu et al. and Liu et al. render obvious a product with anti-wrinkle composition having the retinoid, and a sunscreen composition having the fragrances (retinoid boosters), as recited in the claims.

The references do not specifically teach providing a retinoid booster that is alpha-ionone, as recited in claim 18.

Kobayashi et al. teaches compositions for formulation into cosmetics containing perfumes (see abstract, in particular.) Kobayashi et al. teaches that suitable perfumes for incorporation into cosmetics include ionone (alpha-ionone) (see Constitution section, in particular.)

Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the ionone fragrance of Kobayashi et al. in the compositions of Soares et al, Nakatsu et al, and Liu et al, and in particular in the sunscreen composition of Soares et al, Nakatsu et al, and Liu et al, because Soares et al, Nakatsu et al, and Liu et al. teach such sunscreens having fragrances, and Kobayashi et al. teaches that ionone is a fragrance that is suitable for cosmetic formulations. Thus, one of ordinary skill in the art would have been motivated to provide the fragrances in the composition of Soares et al, Nakatsu et al, and Liu et al. with the expectation of providing a fragrance in the composition that is suitable for cosmetic use.

Claim 16 is rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,914,116 to Soares et al, issued June 22, 1999, in view of U.S Patent No.

Art Unit: 1617

5,965,518 to Nakatsu et al, published October 12, 1999, and further in view of U.S.

Patent No. 5,976,555 to Liu et al, issued November 2, 1999, as applied to claims 1-2, 4-

7, 9-12, 14-5 and 17 above, and further in view of JP 04183797 to Kobayashi et al,

published June 30, 1992, and U.S. Patent No. 5,582,832 to Pillai et al, issued

December 10, 1996.

Suares et al, Nakatsu et al. and Liu et al, are applied as discussed for claims 1-2, 4-7, 9-12, 14-5 and 17 above, and render obvious a product having first and second compartment that are joined together and that isolate the compositions therein, the first compartment keeping out oxygen, with a first composition having a retinoid as recited in the claims, and a second composition having a fragrance corresponding to the retinoid boosters as recited in the claims. Specifically, Suares et al, Nakatsu et al. and Liu et al. render obvious a product with anti-wrinkle composition having the retinoid, and a sunscreen composition having the fragrances (retinoid boosters), as recited in the claims.

The references do not specifically teach providing a retinoid booster that is climbazole in combination with a second retinoid booster selected from the groups consisting of alpha-ionone and damascenone, as recited in claim 16.

The teachings of Kobayashi et al. have been discussed for claim 18 above, and teach providing ionone as a fragrance in cosmetic compositions. Accordingly, it is



Art Unit: 1617

considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the ionone fragrance of Kobayashi et al. in the compositions of Soares et al, Nakatsu et al, and Liu et al, and in particular in the sunscreen composition of Soares et al, Nakatsu et al, and Liu et al, because Soares et al, Nakatsu et al, and Liu et al. teach such sunscreens having fragrances, and Kobayashi et al. teaches that ionone is a fragrance that is suitable for cosmetic formulations. Thus, one of ordinary skill in the art would have been motivated to provide the fragrances in the composition of Soares et al, Nakatsu et al, and Liu et al. with the expectation of providing a fragrance in the composition that is suitable for cosmetic use.

Soares et al, Nakatsu et al, Liu et al. and Kobayashi et al. do not specifically teach providing climbazole in the composition, as recited in claim 16.

Pillai et al. teaches compositions for treating skin that contain an azole ingredient (see abstract, in particular.) Pillai et al. teaches that suitable azoles include climbazole (see column 4, lines 1-21, in particular), and further teaches that the azoles can be formulated into compositions including sunscreen compositions (see column 11, lines 34-55, in particular.) Pillai et al. even exemplifies a sun cream formulation comprising an azole (see Example 8, in particular.)

Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the climbazole of Pillai et al.

Art Unit: 1617

in the composition of Soares et al, Nakatsu et al, Liu et al. and Kobayashi et al, because Soares et al, Nakatsu et al, Liu et al. and Kobayashi et al. teach a product having a topical sunscreen formulation, and Pillai et al. teaches that azole compositions having azoles such as climbazole can be formulation into sunscreens. Thus, one of ordinary skill would have been motivated to provide the climbazole in the sunscreen composition of Soares et al, Nakatsu et al, Liu et al, and Kobayashi et al, with the expectation of providing a suitable ingredient for the sunscreen formulation.

### ***Response to Arguments***

Applicant's arguments regarding the rejections of the claims have been fully considered but they are not persuasive.

Applicants primarily argue that Soares et al. does not teach a product with two compositions that are isolated from each other in different compartments prior to use, and instead Applicants assert that Soares et al. teaches that the separate compositions are sold as a single unit to serve as a reminder for joint usage of the compositions (see page 14 of Remarks submitted January 12, 2007). The Examiner respectfully disagrees. While it is true that Soares et al. teaches that providing the different compositions in a single unit serves as a reminder for joint usage of the compositions, Soares et al. also specifically teaches that the motivation for providing two separate compositions, rather than a single composition having all of the desired actives, is

Art Unit: 1617

because single formulations often compromise the performance of the severally combined actives (see column 1, lines 15-25, in particular.) Thus, Soares et al. teaches a product that allows two compositions to be separated from one another, so that their actives are not compromised, while also allowing for application of both compositions from a single product.

In response to applicant's argument that the references do not recognize the effects of retinoid boosting achieved by the separately stored retinoid boosters, the Examiner notes that fact that applicant has recognized another advantage which would flow naturally from following the suggestion of the prior art cannot be the basis for patentability when the differences would otherwise be obvious. See *Ex parte Obiaya*, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985).

### ***Conclusion***

No claims are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1617


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Abigail M. Cotton whose telephone number is (571) 272-8779. The examiner can normally be reached on 9:30-6:00, M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

AMC



SREENI PADMANABHAN  
SUPERVISORY PATENT EXAMINER